aetherAI Co., Ltd.
TTWSE:780315.05
TWD
-1.25
(-7.67%)
ISIN
TW0007803009
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 108
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Taipei Taiwan
- IPO Date
- Nov 26, 2024
- Website
- aetherai.com
- Similar Companies
- Business
- aetherAI Co., Ltd. is a medical artificial intelligence and healthcare technology company that develops and commercializes AI-powered digital pathology platforms, medical imaging analysis systems, and clinical diagnostic workflow solutions. The company provides a proprietary suite of healthcare software solutions, including aetherSlide, a vendor-neutral digital pathology whole-slide image management and telepathology workflow platform for slide viewing, annotation, case management, and remote consultations; aetherAI Hema, an artificial intelligence-driven automated bone marrow smear differential analysis and cell classification system; aetherAI Endo, a real-time computer-aided detection system for identifying colorectal polyps during colonoscopy procedures; aetherAI LNM, a deep learning diagnostic assistance module for detecting lymph node metastases; aetherAI IHC, an automated immunohistochemistry quantification application for measuring oncological biomarkers including HER2, ER, PR, and Ki-67; and aetherWeb, a cloud-hosted digital pathology educational repository and collaboration platform. The company delivers its digital healthcare solutions to hospital pathology departments, academic medical centers, clinical diagnostic laboratories, and biopharmaceutical research institutions. In recent developments, aetherAI Co., Ltd. completed its public listing on the Taiwan Stock Exchange Innovation Board under the ticker 7803, secured regulatory clearances including United States Food and Drug Administration (FDA) clearance and European Union In Vitro Diagnostic Regulation (IVDR) CE-mark certifications for its core product suite, and expanded its clinical deployment across international healthcare institutions in Japan, Germany, and the United States. Additionally, the company maintains a strategic infrastructure and hardware-software integration partnership with Quanta Computer and Quanta Cloud Technology. aetherAI Co., Ltd. was founded in 2015 and is headquartered in Taipei, Taiwan.